10. References
1. Ishizaka K, Ishizaka T, Hornbrook MM. Physico-chemical properties of human reaginic antibody: IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. The Journal of Immunology.1966;97(1):75-85.
2. Johansson S, Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology. 1967;13(4):381.
3. Gould HJ, Sutton BJ, Beavil AJ, et al. The biology of IGE and the basis of allergic disease. Annual review of immunology.2003;21(1):579-628.
4. Pillai P, Fang C, Chan Y-C, et al. Allergen-specific IgE is not detectable in the bronchial mucosa of nonatopic asthmatic patients.Journal of Allergy and Clinical Immunology.2014;133(6):1770-1772. e1711.
5. Durham SR, Gould HJ, Hamid QA. Local IgE production in nasal allergy.Int Arch Allergy Immunol. 1997;113(1-3):128-130.
6. Ying S, Humbert M, Meng Q, et al. Local expression of ϵ germline gene transcripts and RNA for the ϵ heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma. Journal of allergy and clinical immunology. 2001;107(4):686-692.
7. Wilson DR, Merrett TG, Varga EM, et al. Increases in allergen-specific IgE in BAL after segmental allergen challenge in atopic asthmatics. American journal of respiratory and critical care medicine. 2002;165(1):22-26.
8. Lambrecht B, Peleman R, Bullock G, Pauwels R. Sensitization to inhaled antigen by intratracheal instillation of dendritic cells.Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2000;30(2):214-224.
9. Deckers J, De Bosscher K, Lambrecht BN, Hammad H. Interplay between barrier epithelial cells and dendritic cells in allergic sensitization through the lung and the skin. Immunological reviews.2017;278(1):131-144.
10. Constant S, Schweitzer N, West J, Ranney P, Bottomly K. B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. The Journal of Immunology.1995;155(8):3734-3741.
11. Rivera A, Chen C-C, Ron N, Dougherty JP, Ron Y. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. International immunology. 2001;13(12):1583-1593.
12. Dullaers M, Schuijs MJ, Willart M, et al. House dust mite–driven asthma and allergen-specific T cells depend on B cells when the amount of inhaled allergen is limiting. Journal of Allergy and Clinical Immunology. 2017;140(1):76-88. e77.
13. Wypych TP, Marzi R, Wu GF, Lanzavecchia A, Sallusto F. Role of B cells in T(H) cell responses in a mouse model of asthma. J Allergy Clin Immunol. 2018;141(4):1395-1410.
14. Scadding GW, Eifan A, Lao‐Araya M, et al. Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge. Allergy. 2015;70(6):689-696.
15. Takhar P, Corrigan CJ, Smurthwaite L, et al. Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. Journal of Allergy and Clinical Immunology.2007;119(1):213-218.
16. Santamaria LF, Bheekha R, van Reijsen FC, et al. Antigen focusing by specific monomeric immunoglobulin E bound to CD23 on Epstein-Barr virus-transformed B cells. Hum Immunol. 1993;37(1):23-30.
17. Maurer D, Ebner C, Reininger B, et al. The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation.The Journal of Immunology. 1995;154(12):6285-6290.
18. Maurer D, Fiebiger S, Ebner C, et al. Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha-and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. The Journal of Immunology.1996;157(2):607-616.
19. Van der Heijden F, Van Neerven RJ, Van Katwijk M, Bos J, Kapsenberg M. Serum-IgE-facilitated allergen presentation in atopic disease.The Journal of Immunology. 1993;150(8):3643-3650.
20. Mosconi E, Rekima A, Seitz-Polski B, et al. Breast milk immune complexes are potent inducers of oral tolerance in neonates and prevent asthma development. Mucosal immunology. 2010;3(5):461-474.
21. Lupinek C, Hochwallner H, Johansson C, et al. Maternal allergen-specific IgG might protect the child against allergic sensitization. Journal of Allergy and Clinical Immunology.2019;144(2):536-548.
22. Marchant A, Sadarangani M, Garand M, et al. Maternal immunisation: collaborating with mother nature. The Lancet Infectious Diseases.2017;17(7):e197-e208.
23. Uthoff H, Spenner A, Reckelkamm W, et al. Critical role of preconceptional immunization for protective and nonpathological specific immunity in murine neonates. The Journal of Immunology.2003;171(7):3485-3492.
24. Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nature Reviews Immunology.2006;6(10):761-771.
25. Cooke RA, Barnard JH, Hebald S, Stull A. SEROLOGICAL EVIDENCE OF IMMUNITY WITH COEXISTING SENSITIZATION IN A TYPE OF HUMAN ALLERGY (HAY FEVER). J Exp Med. 1935;62(6):733-750.
26. Platts-Mills TA, von Maur RK, Ishizaka K, Norman PS, Lichtenstein LM. IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release. J Clin Invest. 1976;57(4):1041-1050.
27. Shamji MH LD, Eifan A, Scadding GW, Qin T, Lawson K, SeverML, Macfarlane E, Layhadi JA, Würtzen P, Parkin RV, Sanda S, Harris KM, Nepom GT, Togias A, Durham SR. Differential Induction of Allergen-specific IgA Responses following Timothy Grass Subcutaneous and Sublingual Immunotherapy. . J Allergy Clin Immunol 2021 (in press).
28. Wan T, Beavil RL, Fabiane SM, et al. The crystal structure of IgE Fc reveals an asymmetrically bent conformation. Nature Immunology.2002;3(7):681-686.
29. Zheng Y, Shopes B, Holowka D, Baird B. Dynamic conformations compared for IgE and IgG1 in solution and bound to receptors.Biochemistry. 1992;31(33):7446-7456.
30. Zheng Y, Shopes B, Holowka D, Baird B. Conformations of IgE Bound to its Receptor Fc. epsilon. RI and in Solution. Biochemistry.1991;30(38):9125-9132.
31. Pawankar R, Okuda M, Yssel H, Okumura K, Ra C. Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. The Journal of clinical investigation.1997;99(7):1492-1499.
32. Cameron L, Gounni AS, Frenkiel S, Lavigne F, Vercelli D, Hamid Q. SεSμ and SεSγ switch circles in human nasal mucosa following ex vivo allergen challenge: evidence for direct as well as sequential class switch recombination. The Journal of Immunology.2003;171(7):3816-3822.
33. Corry DB, Kheradmand F. Induction and regulation of the IgE response. Nature. 1999;402(6760):18-23.
34. Humbert M, Grant JA, Taborda-Barata L, et al. High-affinity IgE receptor (FcepsilonRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. American journal of respiratory and critical care medicine. 1996;153(6):1931-1937.
35. Daëron M. Fc RECEPTOR BIOLOGY. Annual Review of Immunology.1997;15(1):203-234.
36. Ravetch JV. Fc receptors. Curr Opin Immunol.1997;9(1):121-125.
37. Saini SS, Richardson JJ, Wofsy C, Lavens-Phillips S, Bochner BS, MacGlashan DW. Expression and modulation of FcϵRIα and FcϵRIβ in human blood basophils. Journal of Allergy and Clinical Immunology.2001;107(5):832-841.
38. Kraft S, Kinet J-P. New developments in FcεRI regulation, function and inhibition. Nature Reviews Immunology. 2007;7(5):365-378.
39. Siraganian RP. Mast cell signal transduction from the high-affinity IgE receptor. Current opinion in immunology. 2003;15(6):639-646.
40. Saini SS, MacGlashan DW, Sterbinsky SA, et al. Down-regulation of human basophil IgE and FcεRIα surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. The Journal of Immunology. 1999;162(9):5624-5630.
41. MacGlashan DW, Bochner BS, Adelman DC, et al. Down-regulation of Fc (epsilon) RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. The Journal of Immunology. 1997;158(3):1438-1445.
42. Asai K, Kitaura J, Kawakami Y, et al. Regulation of mast cell survival by IgE. Immunity. 2001;14(6):791-800.
43. Kinet J-P. The high-affinity IgE receptor (FcεRI): from physiology to pathology. Annual review of immunology. 1999;17(1):931-972.
44. Rajakulasingam K, Durham SR, O’Brien F, et al. Enhanced expression of high-affinity IgE receptor (FcϵRI) α chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages, eosinophils, and dendritic cells. Journal of Allergy and Clinical Immunology.1997;100(1):78-86.
45. Saini SS, Klion AD, Holland SM, Hamilton RG, Bochner BS, MacGlashan Jr DW. The relationship between serum IgE and surface levels of FcϵR on human leukocytes in various diseases: correlation of expression with FcϵRI on basophils but not on monocytes or eosinophils. Journal of allergy and clinical immunology. 2000;106(3):514-520.
46. Allam J-P, Novak N, Fuchs C, et al. Characterization of dendritic cells from human oral mucosa: A new Langerhans’ cell type with high constitutive FcϵRI expression. Journal of Allergy and Clinical Immunology. 2003;112(1):141-148.
47. Foster B, Metcalfe DD, Prussin C. Human dendritic cell 1 and dendritic cell 2 subsets express FcεRI: correlation with serum IgE and allergic asthma. Journal of Allergy and Clinical Immunology.2003;112(6):1132-1138.
48. Kikutani H, Inui S, Sato R, et al. Molecular structure of human lymphocyte receptor for immunoglobulin E. Cell.1986;47(5):657-665.
49. Geha RS, Jabara HH, Brodeur SR. The regulation of immunoglobulin E class-switch recombination. Nature Reviews Immunology.2003;3(9):721-732.
50. Lüdin C, Hofstetter H, Sarfati M, et al. Cloning and expression of the cDNA coding for a human lymphocyte IgE receptor. The EMBO journal. 1987;6(1):109-114.
51. Letellier M, Sarfati M, Delespesse G. Mechanisms of formation of IgE-binding factors (soluble CD23)—I. Fcϵ R II bearing B cells generate IgE-binding factors of different molecular weights.Molecular Immunology. 1989;26(12):1105-1112.
52. McCloskey N, Hunt J, Beavil RL, et al. Soluble CD23 Monomers Inhibit and Oligomers Stimulate IGE Synthesis in Human B Cells*. Journal of Biological Chemistry. 2007;282(33):24083-24091.
53. Novak N, Kraft S, Bieber T. IgE receptors. Current Opinion in Immunology. 2001;13(6):721-726.
54. Yokota A, Yukawa K, Yamamoto A, et al. Two forms of the low-affinity Fc receptor for IgE differentially mediate endocytosis and phagocytosis: identification of the critical cytoplasmic domains. Proc Natl Acad Sci U S A. 1992;89(11):5030-5034.
55. Kay AB. Paul Ehrlich and the Early History of Granulocytes.Microbiol Spectr. 2016;4(4).
56. Turner H, Kinet J-P. Signalling through the high-affinity IgE receptor FcεRI. Nature. 1999;402(6760):24-30.
57. Wedemeyer J, Tsai M, Galli SJ. Roles of mast cells and basophils in innate and acquired immunity. Current opinion in immunology.2000;12(6):624-631.
58. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. Journal of Allergy and Clinical Immunology.2010;125(2):S73-S80.
59. Kim HS, Kawakami Y, Kasakura K, Kawakami T. Recent advances in mast cell activation and regulation. F1000Research. 2020;9.
60. Shade K-TC, Conroy ME, Washburn N, et al. Sialylation of immunoglobulin E is a determinant of allergic pathogenicity.Nature. 2020;582(7811):265-270.
61. Christensen LH, Holm J, Lund G, Riise E, Lund K. Several distinct properties of the IgE repertoire determine effector cell degranulation in response to allergen challenge. Journal of Allergy and Clinical Immunology. 2008;122(2):298-304.
62. Hjort C, Schiøtz PO, Ohlin M, Würtzen PA, Christensen LH, Hoffmann HJ. The number and affinity of productive IgE pairs determine allergen activation of mast cells. Journal of Allergy and Clinical Immunology. 2017;140(4):1167.
63. Hamilton RG, Saito H. IgE antibody concentration, specific activity, clonality, and affinity measures from future diagnostic confirmatory tests. Journal of Allergy and Clinical Immunology.2008;122(2):305-306.
64. Holowka D, Sil D, Torigoe C, Baird B. Insights into immunoglobulin E receptor signaling from structurally defined ligands.Immunological reviews. 2007;217(1):269-279.
65. Gieras A, Linhart B, Roux KH, et al. IgE epitope proximity determines immune complex shape and effector cell activation capacity.Journal of Allergy and Clinical Immunology.2016;137(5):1557-1565.
66. Gieras A, Focke-Tejkl M, Ball T, et al. Molecular determinants of allergen-induced effector cell degranulation. Journal of allergy and clinical immunology. 2007;119(2):384-390.
67. Mudde GC, Bheekha R, Bruijnzeel-Koomen CA. Consequences of IgE/CD23-mediated antigen presentation in allergy. Immunology today. 1995;16(8):380-383.
68. Reginald K, Eckl-Dorna J, Zafred D, et al. Different modes of IgE binding to CD23 revealed with major birch allergen, Bet v 1-specific monoclonal IgE. Immunol Cell Biol. 2013;91(2):167-172.
69. Holm J, Willumsen N, Würtzen PA, Christensen LH, Lund K. Facilitated antigen presentation and its inhibition by blocking IgG antibodies depends on IgE repertoire complexity. Journal of Allergy and Clinical Immunology. 2011;127(4):1029-1037.
70. Villazala-Merino S, Rodriguez-Dominguez A, Stanek V, et al. Allergen-specific IgE levels and the ability of IgE-allergen complexes to cross-link determine the extent of CD23-mediated T-cell activation.Journal of Allergy and Clinical Immunology.2020;145(3):958-967.e955.
71. Selb R, Eckl-Dorna J, Twaroch TE, et al. Critical and direct involvement of the CD23 stalk region in IgE binding. Journal of Allergy and Clinical Immunology. 2017;139(1):281-289. e285.
72. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715-725.
73. Jenmalm M, Björkstén B. Cord blood levels of immunoglobulin G subclass antibodies to food and inhalant allergens in relation to maternal atopy and the development of atopic disease during the first 8 years of life. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2000;30(1):34-40.
74. Macchiaverni P, Arslanian C, Frazao J, et al. Mother to child transfer of IgG and IgA antibodies against Dermatophagoides pteronyssinus. Scandinavian journal of immunology.2011;74(6):619-627.
75. Glovsky MM, Ghekiere L, Rejzek E. Effect of maternal immunotherapy on immediate skin test reactivity, specific rye I IgG and IgE antibody, and total IgE of the children. Annals of allergy.1991;67(1):21-24.
76. Flicker S, Marth K, Kofler H, Valenta R. Placental transfer of allergen-specific IgG but not IgE from a specific immunotherapy-treated mother. Journal of Allergy and Clinical Immunology.2009;124(6):1358.
77. Oykhman P, Kim HL, Ellis AK. Allergen immunotherapy in pregnancy.Allergy, Asthma & Clinical Immunology. 2015;11(1):1-5.
78. Msallam R, Balla J, Rathore AP, et al. Fetal mast cells mediate postnatal allergic responses dependent on maternal IgE. Science.2020;370(6519):941-950.
79. Brandtzaeg P. Mucosal immunity: integration between mother and the breast-fed infant. Vaccine. 2003;21(24):3382-3388.
80. Rekima A, Macchiaverni P, Turfkruyer M, et al. Long‐term reduction in food allergy susceptibility in mice by combining breastfeeding‐induced tolerance and TGF‐β‐enriched formula after weaning. Clinical & Experimental Allergy. 2017;47(4):565-576.
81. Ohsaki A, Venturelli N, Buccigrosso TM, et al. Maternal IgG immune complexes induce food allergen–specific tolerance in offspring.Journal of Experimental Medicine. 2018;215(1):91-113.
82. Victor JR. Allergen-specific IgG as a mediator of allergy inhibition: Lessons from mother to child. Human vaccines & immunotherapeutics. 2017;13(3):507-513.
83. Casas R, Björkstén B. Detection of Fel d 1–immunoglobulin G immune complexes in cord blood and sera from allergic and non‐allergic mothers.Pediatric allergy and immunology. 2001;12(2):59-64.
84. Bernard H, Ah‐Leung S, Drumare MF, et al. Peanut allergens are rapidly transferred in human breast milk and can prevent sensitization in mice. Allergy. 2014;69(7):888-897.
85. Adel-Patient K, Bernard H, Fenaille F, Hazebrouck S, Junot C, Verhasselt V. Prevention of allergy to a major cow’s milk allergen by breastfeeding in mice depends on maternal immune status and oral exposure during lactation. Frontiers in immunology. 2020;11:1545.
86. López-Expósito I, Song Y, Järvinen KM, Srivastava K, Li X-M. Maternal peanut exposure during pregnancy and lactation reduces peanut allergy risk in offspring. Journal of allergy and clinical immunology. 2009;124(5):1039-1046.
87. Järvinen KM, Westfall J, De Jesus M, et al. Role of maternal dietary peanut exposure in development of food allergy and oral tolerance.PloS one. 2015;10(12):e0143855.
88. Macchiaverni P, Rekima A, Turfkruyer M, et al. Respiratory allergen from house dust mite is present in human milk and primes for allergic sensitization in a mouse model of asthma. Allergy.2014;69(3):395-398.
89. Rekima A, Bonnart C, Macchiaverni P, et al. A role for early oral exposure to house dust mite allergens through breast milk in IgE-mediated food allergy susceptibility. Journal of Allergy and Clinical Immunology. 2020;145(5):1416-1429. e1411.
90. Collins A, Roberton D, Hosking C, Flannery G. Bovine milk, including pasteurised milk, contains antibodies directed against allergens of clinical importance to man. International Archives of Allergy and Immunology. 1991;96(4):362-367.
91. Von Mutius E, Vercelli D. Farm living: effects on childhood asthma and allergy. Nature Reviews Immunology. 2010;10(12):861-868.
92. Brick T, Hettinga K, Kirchner B, Pfaffl MW, Ege MJ. The beneficial effect of farm milk consumption on asthma, allergies, and infections: from meta-analysis of evidence to clinical trial. The Journal of Allergy and Clinical Immunology: In Practice. 2020;8(3):878-889. e873.
93. Sozańska B. Raw cow’s milk and its protective effect on allergies and asthma. Nutrients. 2019;11(2):469.
94. Machtinger S, Moss R. Cow’s milk allergy in breast-fed infants: the role of allergen and maternal secretory IgA antibody. Journal of allergy and clinical immunology. 1986;77(2):341-347.
95. Savilahti E, Tainio VM, Salmenperä L, et al. Low colostral IgA associated with cow’s milk allergy. Acta Pædiatrica.1991;80(12):1207-1213.
96. Järvinen KM, Westfall JE, Seppo MS, et al. Role of maternal elimination diets and human milk IgA in the development of cow’s milk allergy in the infants. Clinical & Experimental Allergy.2014;44(1):69-78.
97. Jêvinen K-M, Laine ST, Jêvenpêê A-L, Suomalainen HK. Does low IgA in human milk predispose the infant to development of cow’s milk allergy?Pediatric research. 2000;48(4):457-462.
98. Orivuori L, Loss G, Roduit C, et al. Soluble immunoglobulin A in breast milk is inversely associated with atopic dermatitis at early age: the PASTURE cohort study. Clinical & experimental allergy.2014;44(1):102-112.
99. Ramanan D, Sefik E, Galván-Peña S, et al. An immunologic mode of multigenerational transmission governs a gut Treg setpoint. Cell.2020;181(6):1276-1290. e1213.
100. Bousquet J, Lockey R, Malling H-J. Allergen immunotherapy: therapeutic vaccines for allergic diseases A WHO position paper.Journal of Allergy and Clinical Immunology. 1998;102(4):558-562.
101. Passalacqua G, Compalati E, Canonica GW. Sublingual immunotherapy: clinical indications in the WAO-SLIT position paper. World Allergy Organization Journal. 2010;3(7):216-219.
102. Hoffmann H, Valovirta E, Pfaar O, et al. Novel approaches and perspectives in allergen immunotherapy. Allergy.2017;72(7):1022-1034.
103. Gunawardana NC, Durham SR. New approaches to allergen immunotherapy. Annals of Allergy, Asthma & Immunology.2018;121(3):293-305.
104. Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. Journal of Allergy and Clinical Immunology. 1982;70(4):261-271.
105. Shamji M, Kappen J, Akdis M, et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper.Allergy. 2017;72(8):1156-1173.
106. Shamji MH, Kappen J, Abubakar-Waziri H, et al. Nasal allergen-neutralizing IgG4 antibodies block IgE-mediated responses: Novel biomarker of subcutaneous grass pollen immunotherapy.Journal of Allergy and Clinical Immunology.2019;143(3):1067-1076.
107. Matricardi PM, Dramburg S, Potapova E, Skevaki C, Renz H. Molecular diagnosis for allergen immunotherapy. Journal of Allergy and Clinical Immunology. 2019;143(3):831-843.
108. Rodríguez-Domínguez A, Berings M, Rohrbach A, et al. Molecular profiling of allergen-specific antibody responses may enhance success of specific immunotherapy. Journal of Allergy and Clinical Immunology. 2020;146(5):1097-1108.
109. Van Der Zee JS, Van Swieten P, Aalberse R. Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. The Journal of Immunology. 1986;137(11):3566-3571.
110. van der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood, The Journal of the American Society of Hematology. 2001;97(10):3197-3204.
111. Pilette C, Nouri-Aria KT, Jacobson MR, et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-β expression. The Journal of Immunology. 2007;178(7):4658-4666.
112. Lupinek C, Wollmann E, Valenta R. Monitoring allergen immunotherapy effects by microarray. Current treatment options in allergy.2016;3(2):189-203.
113. Van Neerven R, Wikborg T, Lund G, et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation.The Journal of Immunology. 1999;163(5):2944-2952.
114. Würtzen PA, Lund G, Lund K, Arvidsson M, Rak S, Ipsen H. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin Exp Allergy.2008;38(8):1290-1301.
115. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. Journal of Allergy and Clinical Immunology.2003;112(5):915-922.
116. James LK, Shamji MH, Walker SM, et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. Journal of Allergy and Clinical Immunology.2011;127(2):509-516. e505.
117. Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. The Journal of Immunology.2004;172(5):3252-3259.
118. Heeringa JJ, McKenzie CI, Varese N, et al. Induction of IgG2 and IgG4 B‐cell memory following sublingual immunotherapy for ryegrass pollen allergy. Allergy. 2020;75(5):1121-1132.
119. Shamji MH, Wilcock LK, Wachholz PA, et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses.Journal of immunological methods. 2006;317(1-2):71-79.
120. Shamji M, Ljørring C, Francis J, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy. 2012;67(2):217-226.
121. Valenta R, Campana R, Niederberger V. Recombinant allergy vaccines based on allergen-derived B cell epitopes. Immunology letters.2017;189:19-26.
122. Valenta R, Karaulov A, Niederberger V, et al. Molecular aspects of allergens and allergy. Advances in immunology. 2018;138:195-256.
123. Francis JN, James LK, Paraskevopoulos G, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. Journal of Allergy and Clinical Immunology. 2008;121(5):1120-1125. e1122.
124. Rauber MM, Wu HK, Adams B, et al. Birch pollen allergen‐specific immunotherapy with glutaraldehyde‐modified allergoid induces IL‐10 secretion and protective antibody responses. Allergy.2019;74(8):1575-1579.
125. Ejrnaes A, Svenson M, Lund G, Larsen J, Jacobi H. Inhibition of rBet v 1‐induced basophil histamine release with specific immunotherapy‐induced serum immunoglobulin G: no evidence that FcγRIIB signalling is important. Clinical & Experimental Allergy.2006;36(3):273-282.
126. Shamji MH, Layhadi JA, Scadding GW, et al. Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response.Journal of Allergy and Clinical Immunology. 2015;135(4):913-921. e919.
127. Korosec P, Erzen R, Silar M, Bajrovic N, Kopac P, Kosnik M. Basophil responsiveness in patients with insect sting allergies and negative venom‐specific immunoglobulin E and skin prick test results.Clinical & Experimental Allergy. 2009;39(11):1730-1737.
128. Orengo J, Radin A, Kamat V, et al. Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement.Nature communications. 2018;9(1):1-15.
129. Shamji MH, Singh I, Layhadi JA, et al. Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908-1909 in Cat Allergen-Induced Allergic Rhinitis: A Randomized, Double-blind, Placebo Controlled Trial. American Journal of Respiratory and Critical Care Medicine. 2021(ja).
130. Van Neerven R, Van Roomen C, Thomas W, De Boer M, Knol E, Davis F. Humanized anti-IgE mAb Hu-901 prevents the activation of allergen-specific T cells. International archives of allergy and immunology. 2001;124(1-3):400-402.
131. Dhaliwal B, Yuan D, Pang MO, et al. Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FcεRI. Proceedings of the National Academy of Sciences. 2012;109(31):12686-12691.
132. McDonnell JM, Calvert R, Beavil RL, et al. The structure of the IgE Cɛ2 domain and its role in stabilizing the complex with its high-affinity receptor FcɛRIα. Nature structural biology.2001;8(5):437-441.
133. Wurzburg BA, Garman SC, Jardetzky TS. Structure of the human IgE-Fc Cε3-Cε4 reveals conformational flexibility in the antibody effector domains. Immunity. 2000;13(3):375-385.
134. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. Journal of allergy and clinical immunology.2001;108(2):184-190.
135. Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE 031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects. Clinical & Experimental Allergy. 2014;44(11):1371-1385.
136. Gasser P, Eggel A. Targeting IgE in allergic disease. Current opinion in immunology. 2018;54:86-92.
137. Cox L. Biologics and Allergy Immunotherapy in the Treatment of Allergic Diseases. Immunology and Allergy Clinics.2020;40(4):687-700.
138. Lin C, Lee IT, Sampath V, et al. Combining anti‐IgE with oral immunotherapy. Pediatric Allergy and Immunology.2017;28(7):619-627.
139. Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nature communications. 2020;11(1):1-14.
140. Gauvreau GM, Arm JP, Boulet L-P, et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. Journal of Allergy and Clinical Immunology. 2016;138(4):1051-1059.
141. Maurer M, Giménez-Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria. New England Journal of Medicine.2019;381(14):1321-1332.
142. Pennington LF, Tarchevskaya S, Brigger D, et al. Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nature communications. 2016;7(1):1-12.
143. Davies AM, Allan EG, Keeble AH, et al. Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab. Journal of Biological Chemistry. 2017;292(24):9975-9987.
144. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nature Reviews Immunology. 2008;8(3):205-217.
145. Coyle AJ, Wagner K, Bertrand C, Tsuyuki S, Bews J, Heusser C. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. The Journal of experimental medicine. 1996;183(4):1303-1310.
146. Rosenwasser LJ, Busse WW, Lizambri RG, Olejnik TA, Totoritis MC. Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. Journal of Allergy and Clinical Immunology. 2003;112(3):563-570.
147. Virkud YV, Wang J, Shreffler WG. Enhancing the safety and efficacy of food allergy immunotherapy: a review of adjunctive therapies.Clinical reviews in allergy & immunology. 2018;55(2):172-189.
148. Dantzer J, Wood RA. The use of omalizumab in allergen immunotherapy. Clinical & Experimental Allergy.2018;48(3):232-240.
149. Kim B, Tarchevskaya SS, Eggel A, Vogel M, Jardetzky TS. A time-resolved fluorescence resonance energy transfer assay suitable for high-throughput screening for inhibitors of immunoglobulin E–receptor interactions. Analytical Biochemistry. 2012;431(2):84-89.
150. Eggel A, Baravalle G, Hobi G, et al. Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. Journal of allergy and clinical immunology. 2014;133(6):1709-1719. e1708.
151. Campana R, Marth K, Zieglmayer P, et al. Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: safety, effects, and mechanisms. Journal of Allergy and Clinical Immunology. 2019;143(3):1258-1261.
152. van Hage M, Hamsten C, Valenta R. ImmunoCAP assays: Pros and cons in allergology. Journal of Allergy and Clinical Immunology.2017;140(4):974-977.
153. Skrindo I, Lupinek C, Valenta R, et al. The use of the MeDALL-chip to assess IgE sensitization: a new diagnostic tool for allergic disease?Pediatr Allergy Immunol. 2015;26(3):239-246.
154. Lupinek C, Wollmann E, Baar A, et al. Advances in allergen-microarray technology for diagnosis and monitoring of allergy: the MeDALL allergen-chip. Methods. 2014;66(1):106-119.
155. Wollmann E, Lupinek C, Kundi M, Selb R, Niederberger V, Valenta R. Reduction in allergen-specific IgE binding as measured by microarray: a possible surrogate marker for effects of specific immunotherapy.Journal of Allergy and Clinical Immunology. 2015;136(3):806-809. e807.
156. Schmid JM, Würtzen PA, Dahl R, Hoffmann HJ. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract. Journal of Allergy and Clinical Immunology.2016;137(2):562-570.
157. Lichtenstein LM, Norman PS, Winkenwerder WL, Osler AG. In vitro studies of human ragweed allergy: changes in cellular and humoral activity associated with specific desensitization. The Journal of clinical investigation. 1966;45(7):1126-1136.
158. Mothes N, Heinzkill M, Drachenberg K, et al. Allergen‐specific immunotherapy with a monophosphoryl lipid A‐adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy‐induced blocking antibodies.Clinical & Experimental Allergy. 2003;33(9):1198-1208.
159. Niederberger V, Horak F, Vrtala S, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proceedings of the National academy of Sciences.2004;101(suppl 2):14677-14682.
160. Zieglmayer P, Focke-Tejkl M, Schmutz R, et al. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine. 2016;11:43-57.
161. Akdis CA, Blesken T, Akdis M, Wüthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. The Journal of clinical investigation. 1998;102(1):98-106.
162. Campana R, Moritz K, Marth K, et al. Frequent occurrence of T cell–mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments. Journal of Allergy and Clinical Immunology. 2016;137(2):601-609. e608.
163. Prausnitz C, Küstner H. Studien über die Überempfindlichkeit.Zentralbl Bakteriol. 1921;86:160-169.
164. Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.Journal of Allergy and Clinical Immunology. 2008;122(5):951-960.
165. Scadding GW, Calderon MA, Shamji MH, et al. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.JAMA. 2017;317(6):615-625.
166. Mösges R, Koch A, Raskopf E, et al. Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B‐cell response in seasonal allergic rhinitis patients. Allergy.2018;73(6):1254-1262.